Latest News - Epilepsy & Seizure Disorders

Wednesday, June 13, 2018

Medtronic Deep Brain Stimulation (DBS) Clinician Programmer Receives FDA Approval

Medtronic announced that the U.S. Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. The Activa Programm…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Wednesday, May 23, 2018

New Type of Vertigo Defined That May Be Treatable

Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from serious causes of vertigo (eg, …

Read the full story

Thursday, May 17, 2018

Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed that adding oral CBD to …

Read the full story

Wednesday, May 16, 2018

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures.  The company expects t…

Read the full story

Tuesday, May 01, 2018

Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures

The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce frequency of partial-ons…

Read the full story

Friday, April 27, 2018

Perampanel Safety, Efficacy, and Predictors of Major Response

Perampanel (FYCOMPA; Eisai, Woodcliff Lake, NJ) is approved for use as monotherapy for treatment of partial-onset seizures (POS) with or without secondarily generalized seizures (SGS) and as adjunctiv…

Read the full story

Thursday, April 19, 2018

Advisory Committee Supports Approval of Oral Cannabidiol for Dravet Syndrome and Lennox-Gastaut Syndrome

The Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) unanimously recommended supporting the approval of the investigational cannabidiol oral sol…

Read the full story

Wednesday, April 11, 2018

Everolimus Approved as Adjunctive Treatment for Tuberous Sclerosis-Associated Partial-Onset Seizures

The Food and Drug Administration (FDA) has granted approval for the use of everolimus (Afinitor DISPERZ; Novartis, East Hanover, NJ) to treat tuberous sclerosis complex (TSC)-associated partial onset …

Read the full story

Friday, March 30, 2018

Approval Sought for use of Perampanel in Pediatric Patients With Epilepsy

A supplemental new drug application (sNDA) has been submitted seeking priority review for the use of perampanel (CIII) (FYCOMPA; Eisai Inc, Woodcliff Lake, NJ) for specific pediatric indications.…

Read the full story

Monday, March 26, 2018

New Therapeutic Candidates Identified for SCN8A-Related Epilepsy

Caused by a gain-of-function mutation in the SCN8A gene encoding the Nav1.6 sodium channel, SCN8A-related epilepsy is characterized by developmental delay, seizure onset in infancy (first 18 months of…

Read the full story

Wednesday, March 14, 2018

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatment of convulsive seizure…

Read the full story

Tuesday, February 13, 2018

Pediatricians, Pediatric Neurologists, Patient Advocates, and Industry Partner to Create High-Tech Risk-Screening Tool for Children with Epilepsy

Digital Health Solutions (DHS), the Child Neurology Foundation (CNF), and Greenwich Biosciences began a collaborative effort to develop a digital tool that will prompt providers to communicate with ca…

Read the full story

Tuesday, February 06, 2018

Food and Drug Administration Grants Breakthrough Therapy Designation for ZX008 for Treatment of Dravet Syndrome

Low-dose fenfluramine (ZX008, Zogenix) is classified as an orphan drug for the treatment of two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. Positive results from the first piv…

Read the full story

Tuesday, November 07, 2017

Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years and older. The expanded ind…

Read the full story
Load More